Thioredoxin 1 as a serum marker for ovarian cancer and its use in combination with CA125 for improving the sensitivity of ovarian cancer diagnoses

Biomarkers

Volumn 19, Issue 7, 2014, Pages 604-610

  Park, Byung Joon ^a   Cha, Mee Kyung ^a   Kim, Il Han ^a  

^a PaiChai University   (South Korea)

Author keywords

CA125; Companion marker; Diagnosis; Early phase cancer; Ovarian cancer; Oxidative stress; Thioredoxin 1

Indexed keywords

CA 125 ANTIGEN; THIOREDOXIN 1; MEMBRANE PROTEIN; MUC16 PROTEIN, HUMAN; THIOREDOXIN; TXN PROTEIN, HUMAN;

ADULT; AGED; ANTIGEN ANTIBODY COMPLEX; AREA UNDER THE CURVE; ARTHRITIS; ARTICLE; ATOPIC DERMATITIS; CANCER DIAGNOSIS; CANCER GRADING; CANCER SCREENING; CANCER STAGING; CARDIOVASCULAR DISEASE; COMMUNITY ACQUIRED PNEUMONIA; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; OVARY CANCER; PROTEIN BLOOD LEVEL; RECEIVER OPERATING CHARACTERISTIC; RHEUMATOID ARTHRITIS; SENSITIVITY AND SPECIFICITY; ADOLESCENT; BLOOD; CASE CONTROL STUDY; EARLY DIAGNOSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; MIDDLE AGED; OVARY TUMOR; PATHOLOGY; PREDICTIVE VALUE; UPREGULATION; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AREA UNDER CURVE; CA-125 ANTIGEN; CASE-CONTROL STUDIES; EARLY DETECTION OF CANCER; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; MALE; MEMBRANE PROTEINS; MIDDLE AGED; NEOPLASM STAGING; OVARIAN NEOPLASMS; PREDICTIVE VALUE OF TESTS; ROC CURVE; THIOREDOXINS; UP-REGULATION; YOUNG ADULT;

EID: 84911997456     PISSN: 1354750X     EISSN: 13665804     Source Type: Journal    
DOI: 10.3109/1354750X.2014.956793     Document Type: Article

References (28)

1. Arner ES, Holmgren A. (2000). Physiological functions of thioredoxin and thioredoxin reductase. Eur J Biochem 267:6102-9.
2. Arner ES, Holmgren A. (2006). The thioredoxin system in cancer. Semin Cancer Biol 16:420-6.
3. Bagan P, Berna P, Assouad J, et al. (2008). Value of cancer antigen 125 for diagnosis of pleural endometriosis in females with recurrent pneumothorax. Eur Respir J 31:140-2.
4. Baron JA. (2012). Screening for cancer with molecular markers: progress comes with potential problems. Nat Rev Cancer 12:368-71.
5. Cha MK, Suh KH, Kim IH. (2009). Overexpression of peroxiredoxin I and thioredoxin1 in human breast carcinoma. Exp Clin Cancer Res 28:93.
6. Ferrini R. (1997). Screening asymptomatic women for ovarian cancer: American College of Preventive Medicine practice policy. Am J Prev Med 13:444-6.
7. Fritsche HA, Bast RC. (1998). CA 125 in ovarian cancer: advances and controversy. Clin Chem 44:1379-80.
8. Fuji S, Nanbu Y, Nonogaki H, et al. (1991). Coexpression of adult T-cell leukemia-derived factor, a human thioredoxin homologue, and human papillomavirus DNA in neoplastic cervical squamous epithelium. Cancer 68:1583-91.
9. Hayashi S, Hajiro NK, Makino Y, et al. (1997). Functional modulation of estrogen receptor by redox state with reference to thioredoxin as a mediator. Nucleic Acids Res 25:4035-40.
10. Holmgren A. (1985). Thioredoxin. Annu Rev Biochem 54:237-71.
11. Kobayashi F, Sagawa N, Nanbu Y, et al. (1995). Biochemical and topological analysis of adult T-cell leukaemia-derived factor, homologous to thioredoxin, in the pregnant human uterus. Hum Reprod 10:1603-8.
12. Makino Y, Okamoto K, Yoshikawa N, et al. (1995). Thioredoxin: a redox-regulating cellular cofactor for glucocorticoid hormone action: crosstalk between endocrine control of stress response and cellular antioxidant defense system. J Clin Invest 98:2469-77.
13. Matsutani Y, Yamauchi A, Takahashi R, et al. (2001). Inverse correlation of thioredoxin expression with estrogen receptor-and p53-dependent tumor growth in breast cancer tissues. Clin Cancer Res 7:3430-6.
14. Nakamura H, Masutani H, Tagaya Y, et al. (1992). Expression and growth-promoting effect of adult T-cell leukemia-derived factor: a human thioredoxin homologue in hepatocellular carcinoma. Cancer 69:2091-7.
15. Nakamura H, Nakamura K, Yodoi J. (1997). Redox regulation of cellular activation. Annu Rev Immunol 15:351-9.
16. Nossov V, Amneus M, Su F, et al. (2008). The early detection of ovarian cancer: from traditional methods to proteomics. Can we really do better than serum CA-125 Am J Obstet Gynecol 199:215-13
17. Park BJ, Cha MK, Kim IH. (2014). Thioredoxin 1 as a serum marker for breast cancer and its use in combination with CEA or CA15-3 for improving the sensitivity of breast cancer diagnoses. BMC Res Notes 7:7.
18. Rosen A, Lundman P, Carlsson M, et al. (1995). A CD4 T cell linesecreted factor, growth promoting fornormal and leukemic B cells, identified as thioredoxin. Int Immunol 7:625-33.
19. Rossing MA, Wicklund KG, Cushing-Haugen KL, Weiss NS. (2010). Predictive value of symptoms for early detection of ovarian cancer. J Natl Cancer Inst 102:222-9.
20. Rubartelli A, Bajetto A, Allavena G, et al. (1992). Secretion of thioredoxin by normal and neoplastic cells through a leaderless secretory pathway. J Biol Chem 267:24161-4.
21. Saitoh M, Nishitoh H, Fuji M, et al. (1998). Mammalian thioredoxin is a direct inhibitor of apoptosis signal-regulating kinase (ASK) 1. EMBO J 17:2596-606.
22. Sarandakou A, Protonotariou E, Rizos D. (2007). Tumor markers in biological fluids associated with pregnancy. Crit Rev Clin Lab Sci 44: 151-78.
23. Schenk H, Klein M, Erdbrugger W, et al. (1994). Distinct effects of thioredoxin and antioxidants on the activation of transcription factors NF-kB and AP-1. Proc Natl Acad Sci USA 91:1672-6.
24. Schenk H, Vogt M, Droge W, Schulze-Osthoff K. (1996). Thioredoxin as a potent costimulus of cytokineexpression. J Immunol 156:765-71.
25. Suh KS, Park SW, Castro A, et al. (2010). Ovarian cancer biomarkers for molecular biosensors and translational medicine. Expert Rev Mol Diagn 10:1069-83.
26. Ueno M, Masutani H, Arai AJ, et al. (1999). Thioredoxin-dependent redox regulation of p53-mediated p21 activation. J Biol Chem 274: 35809-15.
27. Wang ML, Huang Q, Yang T. (2009). IgE myeloma with elevated level of serum CA125. J Zhejiang Univ Sci B 10:559-62.
28. Woolston CM, Deen S, Al-Attar A, et al. (2010). Redox protein expression predicts progression-free and overall survival in ovarian cancer patients treated with platinum-based chemotherapy. Free Radic Biol Med 49:1263-72.